![]() |
市場調查報告書
商品編碼
1519420
2024-2032 年按服務、階段、治療領域(腫瘤、心血管疾病、呼吸系統疾病、中樞神經系統和精神疾病等)、最終用途行業和地區分類的臨床試驗用品市場報告Clinical Trial Supplies Market Report by Services, Phase, Therapeutic Area (Oncology, Cardiovascular Diseases, Respiratory Diseases, Central Nervous System And Mental Disorders, and Others), End-Use Industry, and Region 2024-2032 |
IMARC Group年,全球臨床試驗用品市場規模達25億美元。慢性病盛行率的增加、嚴格的監管改革、臨床試驗的全球化、生物技術的進步、生物相似藥和孤兒藥的出現,以及採用區塊鏈和物聯網等創新技術進行供應鏈管理,正在加速市場成長。
臨床試驗用品包括進行嚴格和受控的醫學實驗以評估新藥、療法或醫療設備的安全性和有效性所需的各種材料和資源。它們對於確保臨床試驗的順利執行、為研究人員提供必要的工具和物質來管理治療、收集資料和維持遵守監管標準至關重要。臨床試驗用品包括研究藥物、安慰劑、醫療器材和生物樣本。它們的用途擴展到對人類受試者測試新療法和干涉措施,以評估其治療效果。管理良好的臨床試驗供應的優點包括能夠維持試驗盲法、確保準確的資料收集並最終推進醫學知識。
全球臨床試驗用品市場受到慢性病盛行率不斷上升和對創新療法需求不斷成長的影響。此外,旨在簡化藥物開發流程的監管改革和指導方針促使製藥公司加強對臨床試驗的投資,進一步推動市場成長。與此一致的是,在追求多樣化的患者群體和成本效益的運作的推動下,臨床試驗的全球化產生了對試驗用品的更大需求,這反過來又加速了市場的成長。此外,生物技術和個人化醫療的進步正在增加臨床試驗的複雜性,進一步推動市場成長。除此之外,生物相似藥和孤兒藥的出現擴大了臨床試驗的範圍,從而推動了市場的成長。
慢性病盛行率增加
癌症、糖尿病和心血管疾病等慢性疾病的增加是全球臨床試驗用品市場的重要驅動力。隨著人口老化和生活方式的轉變,這些疾病的盛行率在全球範圍內穩步上升。因此,製藥公司被迫開發新藥和新療法,導致臨床試驗激增。這一趨勢不僅刺激了對臨床試驗用品的需求,而且強調了有效和高效的藥物開發流程來應對這些健康挑戰的迫切性。此外,慢性病特定治療領域(如腫瘤學或神經病學)對專業用品的需求增加了供應鏈的複雜性,使其成為市場參與者的關鍵關注領域。
監理改革與指導方針
世界各地衛生當局和機構發布的監管改革和指南在推動臨床試驗用品市場方面發揮關鍵作用。這些法規旨在標準化和加速藥物開發過程,同時確保病人安全。製藥和生物技術領域的公司必須遵守這些準則,需要嚴格且合規的臨床試驗。因此,為了滿足監管要求,對高品質供應的需求不斷成長。這個促進因素不僅強調了遵守嚴格標準的重要性,而且還強調了高效的供應鏈管理和文件記錄以成功應對複雜監管環境的必要性。
臨床試驗的全球化
臨床試驗的全球化是臨床試驗用品市場的另一個關鍵驅動力。製藥公司擴大在多個國家進行試驗,以接觸不同的患者群體、加速招募並降低成本。這種趨勢在擁有大量患者的新興市場尤其明顯。因此,對臨床試驗用品的需求並不局限於特定地區,而是在全球範圍內擴大。這個促進因素也強調了對強大的物流和供應鏈網路的需求,這些網路可以有效地支援在不同地理位置進行的試驗,這些試驗通常具有不同的監管要求。此外,全球化需要語言、文化和當地基礎設施的適應性,這增加了供應鏈管理流程的複雜性。
The global clinical trial supplies market size reached US$ 2.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032. Increasing prevalence of chronic diseases, stringent regulatory reforms, the globalization of clinical trials, advancements in biotechnology, the emergence of biosimilars and orphan drugs, and the adoption of innovative technologies like blockchain and IoT for supply chain management are accelerating the market growth.
Clinical trial supplies encompass a wide range of materials and resources essential for conducting rigorous and controlled medical experiments to evaluate the safety and efficacy of new drugs, therapies, or medical devices. They are crucial in ensuring the smooth execution of clinical trials, providing researchers with the necessary tools and substances to administer treatments, collect data, and maintain compliance with regulatory standards. Clinical trial supplies consist of investigational drugs, placebos, medical devices, and biological samples. Their uses extend to the testing of novel treatments and interventions on human subjects to assess their therapeutic effects. Advantages of well-managed clinical trial supplies include the ability to maintain trial blinding, ensuring accurate data collection, and ultimately advancing medical knowledge.
The global clinical trial supplies market is influenced by the increasing prevalence of chronic diseases and the growing demand for innovative therapies. Moreover, regulatory reforms and guidelines aimed at streamlining the drug development process have prompted pharmaceutical companies to invest more in clinical trials, further propelling the market growth. In line with this, the globalization of clinical trials, driven by the pursuit of diverse patient populations and cost-effective operations, has created a greater need for trial supplies, which, in turn, is accelerating the market growth. Additionally, advancements in biotechnology and personalized medicine are increasing the complexity of clinical trials, further boosting the market growth. Apart from this, the emergence of biosimilars and orphan drugs has expanded the scope of clinical trials, which is fueling the market growth.
Increasing prevalence of chronic diseases
The rise in chronic diseases, such as cancer, diabetes, and cardiovascular disorders, is a significant driver of the global clinical trial supplies market. With an aging population and shifting lifestyle patterns, the prevalence of these conditions is steadily increasing worldwide. As a result, pharmaceutical companies are compelled to develop new drugs and therapies, necessitating an upsurge in clinical trials. This trend not only fuels the demand for clinical trial supplies but also underscores the urgency for effective and efficient drug development processes to address these health challenges. Furthermore, the need for specialized supplies for specific therapeutic areas within chronic diseases, like oncology or neurology, contributes to the complexity of the supply chain, making it a critical focus area for market players.
Regulatory reforms and guidelines
Regulatory reforms and guidelines issued by health authorities and agencies worldwide play a pivotal role in driving the clinical trial supplies market. These regulations aim to standardize and expedite the drug development process while ensuring patient safety. Companies operating in the pharmaceutical and biotechnology sectors must adhere to these guidelines, necessitating rigorous and compliant clinical trials. As a result, there is a growing demand for high-quality supplies to meet regulatory requirements. This driver not only underscores the importance of adherence to strict standards but also emphasizes the need for efficient supply chain management and documentation to navigate the complex regulatory landscape successfully.
Globalization of clinical trials
The globalization of clinical trials represents another key driver of the clinical trial supplies market. Pharmaceutical companies are increasingly conducting trials in multiple countries to access diverse patient populations, expedite recruitment, and reduce costs. This trend is especially pronounced in emerging markets with significant patient pools. Consequently, the demand for clinical trial supplies is not limited to a specific region but has expanded globally. This driver also highlights the need for robust logistics and supply chain networks that can efficiently support trials conducted in various geographical locations, often with differing regulatory requirements. Furthermore, globalization necessitates adaptability in terms of language, culture, and local infrastructure, adding complexity to the supply chain management process.
IMARC Group provides an analysis of the key trends in each segment of the global clinical trial supplies market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on services, phase, therapeutic area, and end-use industry.
Product Manufacturing
Packaging, Labeling and Storage
Logistics and Distribution
Logistics and distribution dominates the market
A detailed breakup and analysis of the market based on the services has also been provided in the report. This includes product manufacturing, packaging, labeling and storage, and logistics and distribution. According to the report, logistics and distribution represented the largest segment.
The logistics and distribution segment within the clinical trial supplies market is witnessing substantial growth due to the increasing globalization of clinical trials. As pharmaceutical companies expand their trials to diverse geographic locations, the need for efficient and reliable logistics and distribution networks becomes paramount. This includes ensuring timely delivery of supplies to various trial sites worldwide. Moreover, advancements in technology, such as the integration of blockchain and IoT, are revolutionizing supply chain management. These innovations enhance real-time tracking and monitoring of clinical trial supplies, leading to increased efficiency and reduced wastage. In line with this, the COVID-19 pandemic has underscored the importance of resilient and adaptable supply chains. Companies are now investing in robust logistics to ensure the uninterrupted flow of critical supplies, even in times of crisis. Furthermore, the emphasis on patient-centric approaches in clinical trials has led to the need for patient kits and direct-to-patient shipments. This trend requires specialized logistics solutions tailored to individual patient needs.
Phase I
Phase II
Phase III
Others
Phase III dominates the market
The report has provided a detailed breakup and analysis of the market based on the phase. This includes phase I, phase II, phase III, and others. According to the report, phase III represented the largest segment.
The phase III segment dominates the market as it represents the pivotal stage in evaluating a drug's efficacy and safety, making it a critical step in the regulatory approval process. This regulatory focus drives pharmaceutical companies to invest significantly in phase III trials. Moreover, as drugs progress through earlier phases, the sample size required for phase III trials increases substantially, translating into higher demand for clinical trial supplies. Additionally, phase III trials often involve a global patient population, necessitating comprehensive supply chain logistics to ensure the timely delivery of materials to diverse sites. In line with this, the increasing complexity of drug development, particularly in areas like oncology and rare diseases, necessitates larger and more complex phase III trials. This complexity includes the need for specialized supplies, patient-centric approaches, and adaptive trial designs. Furthermore, the demand for phase III trials is influenced by market dynamics, including competition and the need for differentiation in therapeutic areas. Companies seek to demonstrate superior efficacy and safety profiles, making phase III trials a pivotal stage in their product development strategies.
Oncology
Cardiovascular Diseases
Respiratory Diseases
Central Nervous System (CNS) And Mental Disorders
Others
Oncology dominates the market
A detailed breakup and analysis of the market based on the therapeutic area has also been provided in the report. This includes oncology, cardiovascular diseases, respiratory diseases, central nervous system (CNS) and mental disorders, and others. According to the report, oncology represented the largest segment.
The oncology segment is experiencing significant growth within the clinical trial supplies market, primarily driven by the escalating global incidence of cancer. With cancer being one of the leading causes of mortality worldwide, pharmaceutical companies are increasingly investing in oncology-focused clinical trials to develop novel therapies and treatments. Moreover, advances in cancer research and the identification of specific biomarkers have led to the development of targeted therapies. This trend has necessitated the need for specialized clinical trial supplies tailored to the unique requirements of oncology trials, such as precision medicine tools and specialized diagnostics. Furthermore, regulatory agencies are expediting approvals for promising oncology drugs, encouraging pharmaceutical companies to accelerate their research efforts. Consequently, there is a growing demand for clinical trial supplies to support these fast-paced trials. Besides this, collaborations between pharmaceutical firms and academic institutions or research organizations are fostering innovation in oncology research. This partnership-driven approach is increasing the scope and complexity of clinical trials, thereby boosting the demand for clinical trial supplies.
Medical Device Industry
Biopharmaceuticals Industry
Pharmaceuticals Industry
Others
Pharmaceuticals industry hold the largest share in the market
A detailed breakup and analysis of the market based on the end-use industry has also been provided in the report. This includes medical device industry, biopharmaceuticals industry, pharmaceuticals industry, and others. According to the report, pharmaceuticals industry represented the largest segment.
The pharmaceuticals segment is experiencing substantial growth driven by the increasing global burden of chronic diseases, including cancer, cardiovascular ailments, and diabetes, which has led to a heightened demand for innovative drugs and therapies. Moreover, regulatory reforms and evolving healthcare policies are shaping the industry landscape. Stringent regulations and guidelines, particularly in developed markets, necessitate compliance and adherence to safety standards. This environment promotes innovation and the development of high-quality pharmaceutical products. Furthermore, advancements in biotechnology and genomics have ushered in an era of precision medicine. Tailoring treatments to individual patient profiles is becoming more common, driving research and development efforts in the pharmaceutical sector. Apart from this, the emergence of biosimilars and orphan drugs is expanding the pharmaceutical market's scope. Biosimilars offer cost-effective alternatives to biologics, while orphan drugs target rare diseases, presenting lucrative opportunities for pharmaceutical companies.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest clinical trial supplies market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest segment.
North America's clinical trial supplies market is witnessing substantial growth, fueled by the region's well-established pharmaceutical and biotechnology sector, coupled with a robust healthcare infrastructure, creates a conducive environment for clinical trials. Moreover, regulatory agencies like the FDA in the United States have streamlined approval processes, encouraging pharmaceutical companies to conduct trials in the region. In line with this, North America's diverse patient populations and access to specialized healthcare facilities make it an attractive destination for clinical trials across various therapeutic areas. Furthermore, the increasing prevalence of chronic diseases, such as diabetes and cancer, drives the demand for clinical trials to develop innovative treatments. Additionally, the emergence of cutting-edge technologies like genomics and precision medicine is propelling North America's position as a hub for advanced clinical research. The pandemic's impact has also accelerated the adoption of virtual and decentralized trials in the region, further contributing to market growth.
The competitive landscape of the clinical trial supplies market is characterized by a dynamic interplay of various stakeholders, each contributing to the industry's growth and evolution. Service providers in this sector offer a wide range of solutions, including clinical packaging, labeling, distribution, and logistics services, making it a highly specialized and competitive field. Key players in the market differentiate themselves through their global reach, technological capabilities, regulatory compliance, and ability to cater to diverse therapeutic areas. These companies often form strategic partnerships with pharmaceutical and biotechnology firms to provide end-to-end solutions for clinical trials. In addition to established companies, the market also sees the emergence of niche players focusing on specific areas such as direct-to-patient services, temperature-sensitive logistics, and innovative supply chain technologies. These specialized firms cater to the evolving needs of the industry, offering unique solutions to enhance efficiency and cost-effectiveness. Moreover, the market's competitive landscape is influenced by regulatory changes, as compliance with stringent standards is imperative. This factor underscores the importance of choosing suppliers with a proven track record in maintaining the highest quality and compliance levels.
Almac Group Ltd.
Catalent Pharma Solutions Inc.
DHL
Parexel
Thermo Fisher Scientific Inc.
PCI Services
Sharp Clinical
Biocair
Movianto
In September 2023, Parexel and Partex have inked a deal aiming to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for biopharmaceutical customers worldwide and de-risk the assets in their portfolios.
In September 2023, DHL Express commenced the full-fledged operation of Incheon Gateway after it invested €131 million to expand the Gateway in 2019. The investment is DHL Express's largest in South Korea to date, making Incheon Gateway the largest gateway in the Asia Pacific.
In June 2021, Catalent announced that it has expanded its integrated development, manufacturing and supply solution, OneBio(R) Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.